DUBLIN–()–The “Dysmenorrhea – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s providing.

This ‘Dysmenorrhea-Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Dysmenorrhea, historic and forecasted epidemiology in addition to the Dysmenorrhea market tendencies within the United States, EU-5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The dysmenorrhea market report gives present remedy practices, rising medication, Dysmenorrhea market share of the person therapies, present and forecasted Dysmenorrhea market dimension from 2017 to 2030 segmented by seven main markets. The Report additionally covers present Dysmenorrhea remedy follow/algorithm, market drivers, market boundaries and unmet medical must curate better of the alternatives and assesses underlying potential of the market.

Dysmenorrhea Epidemiology

The Dysmenorrhea epidemiology division gives the insights about historic and present Dysmenorrhea affected person pool and forecasted development for every seven main nations. It helps to acknowledge the causes of present and forecasted tendencies by exploring quite a few research and views of key opinion leaders. This a part of The report additionally gives the recognized affected person pool and their tendencies together with assumptions undertaken.

Key Findings

The illness epidemiology lined within the report gives historic in addition to forecasted Dysmenorrhea epidemiology [segmented as Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea), Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea, Severity-specific Prevalent Cases of Primary dysmenorrhea, Severity-specific Prevalent Cases of Secondary dysmenorrhea, Treated cases of Primary and Secondary Dysmenorrhea] state of affairs of Dysmenorrhea within the 7MM masking the United States, EU5 nations (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Dysmenorrhea Emerging Drugs

Relugolix: Myovant Sciences GmbH/ Takeda

Myovant Sciences is growing its potential drug Relugolix, which is a small molecule consumed orally and its mechanism of motion contains performing as a GnRH receptor antagonist, for the remedy of uterine fibroids and endometriosis. Relugolix is essentially the most anticipated part III program for the remedy of endometriosis-related ache. For this candidate, Takeda has industrial rights for Japan together with some components of Asia. In different areas, Myovant Sciences holds commercialization rights. Myovant was fashioned by Takeda and Roivant Sciences in June 2016.

Yselty (Linzagolix; OBE2109): ObsEva

Yselty (beforehand often known as Linzagolixx, OBE2109) by ObsEva is a novel, oral, as soon as-each day, GnRH receptor antagonist with the tagline greatest-in-class profile. As per the corporate, the facet which makes it totally different from the opposite marketed GnRH, is that it has the potential to supply efficient administration of endometriosis-related ache whereas mitigating bone mineral density loss and different opposed results sometimes related to at present accepted remedies.

FSN-013 (Estetrol/ Drospirenone): Fuji Pharma

FSN-013 is a fifth technology mixed oral contraceptive drug of Fuji Pharma composed of estetrol (a pure estrogen) and drospirenone. As of now, it has exhibited a few of the eye-catching traits equivalent to improved bleeding management as in comparison with different medication. Along with this, it additionally has decrease lipid impression, and decrease interplay amongst different medication.

Pure Femme Tablets: Pure Green

Pure Green Pharmaceuticals is an rising the US-based mostly biotech begin-up, on the forefront of analysis into the therapeutic qualities of hashish. Currently, a part II (NCT04091789) scientific trial is in its recruiting stage which is anticipated to incorporate 30 sufferers.

Dysmenorrhea Market Outlook

Key Findings

Dysmenorrhea market within the 7MM is predicted to alter within the research interval 2017-2030.The therapeutic market of Dysmenorrhea in seven main markets was discovered to be USD 7,430 million in 2017 which is predicted to extend throughout research interval (2017-2030).

Key Topics Covered:

1. Key Insights

2. Executive Summary of Dysmenorrhea

3. SWOT Analysis

4. Epidemiology and Market Methodology

5. Dysmenorrhea: Market Share (%) Distribution Overview at a Glance: By Country

6. Dysmenorrhea: Disease Background and Overview

6.1. Types of Dysmenorrhea

6.2. Risk Factors

6.3. Signs and Symptoms

6.4. Pathophysiology

6.5. Diagnosis

6.6. Diagnostic Algorithm

6.7. Diagnostic Guidelines

6.7.1. National Institute for Health and Care Excellence (NICE) Guidelines

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale

7.3. Epidemiology Scenario: 7MM

8. Current Treatment Practices

8.1. Pharmacological Treatments

8.1.1. NSAIDs

8.1.2. Hormonal contraception

8.1.3. Gonadotropin-releasing hormone (GnRH) analogs

8.2. Surgery

8.2.1. Removal of the uterus (hysterectomy) and ovaries (oophorectomy)

8.2.2. Laparoscopic uterine nerve ablation and laparoscopic presacral neurectomy

8.3. Non-Pharmacological Treatments

8.3.1. Transcutaneous electrical nerve stimulation (TENS)

8.3.2. Supportive Therapies

8.4. Treatment Algorithms

8.5. Guideline of Dysmenorrhea

8.5.1. American College of Obstetricians and Gynecologists (ACOG) suggestions for Dysmenorrhea and Endometriosis within the Adolescent

8.5.2. NICE Recommendations: Endometriosis (2017)

8.5.3. Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 version

8.5.4. Guideline of the European Society of Human Reproduction and Embryology (ESHRE) for Endometriosis-associated ache: 2013

9. Unmet Needs

10. Patient Journey

11. Key Endpoints in Dysmenorrhea Clinical Trials

12. Marketed Therapies

12.1. Marketed Key Cross

12.2. Orilissa (Elagolix): AbbVie/ Neurosciences Biosciences

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activities

12.2.4. Pivotal Clinical Trial

12.2.5. Ongoing Clinical Trial Activity

12.3. Jemina Tablets (levonorgestrel – ethinylestradiol compound formulation): Nobelpharma/ASKA Pharmaceutical

12.4. Visanne (Dinagest): Mochida/Bayer Schering Pharma AG

13. Emerging Therapies

13.1. Yselty (Linzagolix; OBE2109): ObsEva

13.1.1. Product Description

13.1.2. Other Developmental Activities

13.1.3. Clinical Development

13.1.4. Safety and Efficacy

13.2. Relugolix (TAK-385): Myovant Sciences/Takeda

13.3. Pure Femme Tablets: Pure Green

13.4. FSN-013 (Estetrol/ Drospirenone): Fuji Pharma

13.5. NS-580: Nippon Shinyaku

14. Conjoint Analysis of Dysmenorrhea Therapies

15. Dysmenorrhea: Seven Major Market Analysis

15.1. Key Findings

15.2. Market Outlook

For extra details about this drug pipelines report go to https://www.researchandmarkets.com/r/pql54m

Source link